Clinical trials
Prostate Cancer Metastatic Disease clinical trials
Below are recruiting prostate cancer metastatic disease clinical trials, each written for real people, not researchers. We’re tracking 594 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05818683RecruitingPhase 1
Pasritamig plus other drugs for advanced prostate cancer
This Phase 1 study tests pasritamig (JNJ-78278343) combined with other prostate cancer treatments in people with advanced prostate cancer that has spread. It aims to find the safest dose and see whether the combinations can help slow the cancer.
Sarasota, FloridaAges 18 years+ - NCT06830850RecruitingPhase 1
Testing a new drug for metastatic prostate cancer
This trial tests a new drug, HRS-5041, for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to see if the drug is safe and can help control the cancer.
Sydney, New South WalesAges 18 years+ - NCT06702995RecruitingPhase 1/Phase 2
Study of XNW5004 plus enzalutamide for advanced prostate cancer
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
Jinan, ShandongAges 18 years+ - NCT07206056RecruitingPhase 1/Phase 2
Study of tulmimetostat and luxdegalutamide for advanced prostate cancer
This trial tests a new combination of two drugs for men whose prostate cancer has spread and is no longer controlled by hormone therapy. The study aims to see if this treatment can help shrink tumors or slow the disease.
Denver, ColoradoAges 18 years+ - NCT07089550Recruiting
PSMA PET scans to track treatment response in advanced prostate cancer
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
Bologna, ItalyAges 18 years+ - NCT06387056RecruitingPhase 2
Gene-guided hormone therapy before prostate cancer surgery
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
Xiamen, FujianAges 18 years+ - NCT06682390Recruiting
Race and diet study for men on hormone therapy
This study explores how race affects nutrition for men receiving hormone therapy (ADT) for prostate cancer. It may help researchers understand if different dietary approaches are needed based on race.
Los Angeles, CaliforniaAges 18 years+ - NCT06991556RecruitingPhase 2
Testing JSB462 plus abiraterone for advanced prostate cancer
This trial tests a new drug called JSB462 combined with abiraterone in men with prostate cancer that has spread to other parts of the body and is still responding to hormone therapy. The goal is to see if this combination works better than current treatments.
La Jolla, CaliforniaAges 18 years+ - NCT06629779RecruitingPhase 3
Study of Mevrometostat for Advanced Prostate Cancer
This study tests a new drug called mevrometostat for men with a specific type of advanced prostate cancer that has spread and is still growing despite hormone therapy. It aims to see if the drug can help control the cancer.
Chandler, ArizonaAges 18 years+ - NCT04704505RecruitingPhase 2
Testosterone-like treatment plus radium for bone-spread prostate cancer
This trial studies whether adding a testosterone-related therapy (BAT) to radium-223 can better control prostate cancer that has spread mainly to the bones. It may help shrink tumors in the bone and slow PSA rises, which are a common marker of prostate cancer activity.
Baltimore, MarylandAges 18 years+ - NCT05656794RecruitingPhase 2
Radiation after treatment for prostate cancer that has spread
This trial studies whether adding a targeted course of radiation to the prostate area after initial systemic treatment can improve outcomes for people with metastatic prostate cancer. It may help control the cancer by treating remaining disease after medicines have started working.
Toronto, OntarioAges 18–100 - NCT06978296Recruiting
HIMARS: Stereotactic radiation for prostate cancer spread
This trial tests adding targeted radiation (SRT) to bone or lymph node metastases in men with prostate cancer that has continued to grow despite hormone therapy, chemo, or other treatments. The goal is to see if radiation can help control the disease and improve outcomes.
Saint-HerblainAges 18 years+ - NCT06661122Recruiting
Darolutamide with ADT and docetaxel for low-volume metastatic prostate cancer
This study looks at how safe and effective the combination of darolutamide (a tablet), hormone therapy (ADT), and chemotherapy (docetaxel) is for Japanese men with prostate cancer that has spread in a limited way (low volume). It observes people in regular medical care, not in a research setting.
Multiple LocationsAges 18 years+ - NCT06927635RecruitingPhase 2
SBRT vs standard care for prostate cancer that has spread to a few spots
This trial tests whether targeted radiation (SBRT) to a few sites of cancer spread can help men whose prostate cancer has stopped responding to hormone therapy but has not spread to many places. You may benefit if you have a limited number of growing spots outside the brain or spine.
Toronto, OntarioAges 18–100 - NCT05125016RecruitingPhase 1/Phase 2
Study drug for advanced prostate cancer after standard treatments
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
Palo Alto, CaliforniaAges 18 years+ - NCT07395804Recruiting
How darolutamide works for advanced prostate cancer in Germany
This study looks at how well a drug called darolutamide (a type of hormone therapy) works in everyday medical practice for men with advanced prostate cancer that has spread. It is for men who are already starting this treatment with their doctor and will help doctors understand how it works in real life.
LocationsAges 18 years+ - NCT04916613RecruitingPhase 3
ADT plus darolutamide for vulnerable newly metastatic prostate cancer
This trial studies whether adding darolutamide to standard hormone therapy (ADT) helps men with newly diagnosed metastatic prostate cancer who are physically vulnerable. It aims to control the cancer better while checking safety and how well treatment is tolerated in this group.
CharleroiAges 18 years+ - NCT07365995RecruitingPhase 3
New drug for advanced prostate cancer vs. standard chemo
This trial tests a new drug called BNT324 against the standard chemotherapy docetaxel for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the new treatment can help control the cancer better.
Aurora, ColoradoAges 18 years+ - NCT06228053RecruitingPhase 2
Study of SX-682 plus enzalutamide for men with advanced prostate cancer
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
Los Angeles, CaliforniaAges 18 years+ - NCT07287150RecruitingPhase 2
Inavolisib for metastatic castration-resistant prostate cancer
This trial tests a new drug called Inavolisib for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can help slow the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06227156RecruitingPhase 2
Targeted drug for HER2-positive castration-resistant prostate cancer
This trial tests a new drug called Disitamab Vedotin for men with advanced prostate cancer that is no longer responding to hormone therapy. The drug targets a protein called HER2 on cancer cells to try to shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07244341RecruitingPhase 1
Valemetostat and darolutamide for advanced prostate cancer
This trial tests a new combination of two drugs (valemetostat and darolutamide) for men with metastatic castration-resistant prostate cancer that has worsened after prior treatment. The goal is to see if the combination can slow cancer growth.
La Jolla, CaliforniaAges 18 years+ - NCT06531499RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
Los Angeles, CaliforniaAges 18–100 - NCT06533644RecruitingPhase 2
SYNC-T therapy study for advanced prostate cancer
This trial tests a new treatment called SYNC-T Therapy (SV-102) for men with metastatic castration-resistant prostate cancer that has progressed after other treatments. The therapy is given directly into a tumor to help your immune system fight the cancer.
Phoenix, ArizonaAges 18 years+
Hear when a new Prostate Cancer Metastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer metastatic disease?
- Yes. Clin2 currently lists 594 recruiting prostate cancer metastatic disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer metastatic disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer metastatic disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metastatic Castration-resistant Prostate Cancer
- Metastatic Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Metastatic Castration-Resistant Prostate Cancer Patients
- Non-metastatic Castration-resistant Prostate Cancer
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.